Faster, More Accurate
Cancer Classification
- Decreases diagnostic imaging and other
diagnostic procedures.
- Improves disease prognosis, potential
outcomes, and therapy options.
- Reduces outside consults and referrals for
second opinions.
- Shortens time to initiation of therapy.
- Assists with insurance coverage of selected drug therapies.
- Facilitates clinical trial enrollment.
- Results in cost savings.
|
|
Research Collaborations
- Harvard Medical School / MGH, Boston, MA
- MD Anderson Cancer Center, Houston, TX
- Scripps Memorial Hospital, La Jolla, CA
- Sharp Medical Center, San Diego, CA
Link to publications |
Sample and Technical Information
- Robust real-time RT-PCR assay.
- Requires one adjacent H&E and two unstained slides from formalin-fixed, paraffin embedded
specimens.
- Performed in a CAP accredited, CLIA-certified
laboratory.
- Results typically available within 3-5 working days of receipt of sample.
|
References:
1 Ma, et al. Molecular Classification of Human Cancers Using a 92-Gene
Real Time Quantitative Polymerase Chain Reaction Assay. Archives of
Pathology and Laboratory Medicine, 130: 465-473, 2006.
2 Varadhachary, GR et al. Diagnostic Strategies for Unknown Primary
Cancer. Cancer. 100:1776-1785, 2004.
3 Abbruzzese, JL et al. Analysis of a diagnostic strategy for patients with
suspected tumors of unknown origin. J Clin Oncol., 13:2094-2103, 1995.
4 Schapira DV, Jarrett AR. The need to consider survival, outcome, and
expense when evaluating and treating patients with unknown primary
carcinoma. Arch Intern Med.;155:2050-2054, 1995.
| TOP |
|
